US FDA: GLP-1 receptor agonists are required to change safety labels because they may increase the risk of rare but serious eye diseases.

Zhitongcaijing · 2d ago
US FDA: GLP-1 receptor agonists are required to change safety labels because they may increase the risk of rare but serious eye diseases.